Get started
Author

Qinpei Cheng

Observed name: Qinpei CHENG
ORCID: 0000-0003-4643-232X
Observed ORCID: 0000-0003-4643-232X
OpenAlex ID: A5009577903
NAT10-mediated upregulation of GAS5 facilitates immune cell infiltration in non-small cell lung cancer via the MYBBP1A-p53/IRF1/type I interferon signaling axis
2024 · Zimu Wang, Jing Luo, et al. · Cell Death Discovery · 37
Hippocampal microglia CD40 mediates NPSLE cognitive dysfunction in mice
2021 · Xiaoyue Qiao, Hailin Wang, et al. · Journal of Neuroimmunology · 33
Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis
2024 · Yueying Chen, Hedong Han, et al. · Cancer Immunology Immunotherapy · 19
Intrinsic STING of CD8 + T cells regulates self-metabolic reprogramming and memory to exert anti-tumor effects
2025 · Qiuli Xu, Xin Hua, et al. · Cell Communication and Signaling · 18
Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion
2025 · Qinpei Cheng, Xueying Zuo, et al. · Respiratory Research · 15
PDF
Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy
2024 · Yuxin Jiang, Jingyuan Xie, et al. · International Immunopharmacology · 10
A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer
2024 · Xueying Zuo, Qinpei Cheng, et al. · International Immunopharmacology · 9
A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patients
2024 · Yuxin Jiang, Yueying Chen, et al. · Cancer Immunology Immunotherapy · 7
PDF
Radiomicsmetabolic signature profiles for advanced non-small cell lung cancer with chemoimmunotherapy by reflecting biological function and survival
2024 · Yuxin Jiang, Tao Liu, et al. · Translational Lung Cancer Research · 5
Intrapleural anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer with malignant pleural effusion: a prospective, single-arm, single-center, phase I trial
2025 · Yuting Cui, Qiuxia Wu, et al. · Clinical & Translational Oncology · 2
Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis
2024 · Yueying Chen, Hedong Han, et al. · Cancer Immunology Immunotherapy · 2
PDF
VISTA expressed on tumor cells is regulated by m6A and influences immune microenvironment through STAT3/CCL22 in NSCLC
2025 · Hao Xu, Kaikai Shen, et al. · Journal of Translational Medicine · 1
PDF
Lymph nodes rather than pleural metabolic activity in 18F-FDG PET/CT correlates with malignant pleural effusion recurrence in advanced non-small cell lung cancer
2024 · Yuxin Jiang, Tao Liu, et al. · Translational Lung Cancer Research · 1
Targeting Iron Regulatory Protein 2 in Tumor-associated Macrophages Activates Antitumor Immunity in NSCLC via Modulating SphK1-PD-L1 Axis
2026 · Jiawen Ding, Qinpei Cheng, et al. · International Journal of Biological Sciences
PDF
CD39+CD8+ T cell infiltration is associated with clinical outcomes of subsequent immunotherapy in advanced EGFR-mutant non-small cell lung cancer
2026 · Wanjun Lu, Qiuxia Wu, et al. · Therapeutic Advances in Medical Oncology
Advances in NKG2D Receptor-Ligand Axis in Solid Tumor Immunotherapy
2026 · Qinpei CHENG, Tangfeng LYU · DOAJ (DOAJ: Directory of Open Access Journals)
Impact of chronic obstructive pulmonary disease on the prognosis of patients with extensive-stage small-cell lung cancer treated with chemoimmunotherapy
2026 · Yuxin Jiang, Yu Li, et al. · Translational Lung Cancer Research
Works count: 17
Citation count: 159
H-index: 7
I10-index: 6
Year
Topic
Type